Antibody response to COVID-19 vaccination in patients with lymphoma림프종 환자에서 코로나19 예방접종에 대한 항체 반응Observational Study Published on 2022-05-012022-09-12 Journal: International journal of hematology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome anti-S anti-S antibody antibody level Antibody Response CD19 CD4 Cell clinically conducted coronavirus correlated COVID-19 COVID-19 vaccination COVID-19 vaccine Effectiveness Efficacy Factor help IgM Immunoglobulin increased risk interleukin 2 lymphoma lymphoma cell median MONITOR Multivariate analysis Patient Peripheral blood predict prospective observational study Protective receiving receptor SARS-CoV-2 vaccination second dose serum significantly the antibody response the SARS-CoV-2 the vaccine Treatment Vaccine White blood cell [DOI] 10.1007/s12185-022-03305-z PMC 바로가기 [Article Type] Observational Study
COVID-19 Vaccines in Pancreatic Transplant Recipients: A Single-Center Observative Study췌장 이식 환자의 코로나19 백신: 단일 센터 관찰 연구Article Published on 2022-05-012022-09-12 Journal: Transplantation proceedings [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration antibody Care Course COVID-19 COVID-19 virus death dose doses evaluate had no highest IgM and IgG Immunoglobulin immunosuppressive drugs Infection influenza-like symptom kidney Most patient mRNA vaccine multi-organ failure pancrea Patient performed PROTECT recipient respond response to vaccination Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic serious complication serum Severe infection the vaccine therapeutic Transplant vaccination [DOI] 10.1016/j.transproceed.2022.03.002 PMC 바로가기 [Article Type] Article
Partisanship, Messaging, and the COVID-19 Vaccine: Evidence From Survey ExperimentsRandomized Controlled Trial Published on 2022-05-012022-10-04 Journal: American journal of health promotion : AJHP [Category] COVID19(2023년), SARS, 임상, [키워드] 95% confidence interval adjusted odds ratio analyzed AOR COVID-19 COVID-19 vaccination COVID-19 vaccine Effect elite messaging experiment had no independent Likert scale Mann-Whitney U multivariate logistic regression partisanship. President produced Randomized reported respondent Significant significant effect Support survey the vaccine Two-arm vaccinate vaccination intention vaccination intentions widespread [DOI] 10.1177/08901171211049241 PMC 바로가기 [Article Type] Randomized Controlled Trial
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosusObservational Study Published on 2022-05-012022-10-05 Journal: Clinical Rheumatology [Category] COVID19(2023년), SARS, 임상, [키워드] (MeSH NLM): Coronavirus Autoimmune diseases BNT162b2 BNT162b2 vaccine COVID-19 Department died disease dose doses Effect Hospitalized Hydroxychloroquine identify immunization immunized intensity Local lower risk Mild occurred Pain Patient Pfizer Point predominant presenting renal Renal involvement risk SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine severity side Side effect SLE SLE patient Symptom systemic systemic lupus erythematosus the vaccine use of hydroxychloroquine vaccination Vaccines [DOI] 10.1007/s10067-021-05980-5 PMC 바로가기 [Article Type] Observational Study
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021유럽에서 델타 순환이 우세한 동안 1차 진료 및 지역사회 수준에서 COVID-19에 대한 완전한 1차 백신 접종의 효과: 다중 센터 분석, I-MOVE-COVID-19 및 ECDC 네트워크, 2021년 7월~8월Multicenter Study Published on 2022-05-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory symptom acute respiratory symptoms Analysis circulation Community Complete Course COVID-19 COVID-19 vaccine Delta delta variant ECDC Effectiveness Europe European country janssen multicentre multicentre study Older predominant primary care Sample size SARS-CoV-2 symptomatic symptomatic infection test-negative design tested the SARS-CoV-2 the vaccine vaccination vaccination against COVID-19 Vaccine vaccine effectiveness while with COVID-19 [DOI] 10.2807/1560-7917.ES.2022.27.21.2101104 PMC 바로가기 [Article Type] Multicenter Study
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccineBNT162b2 및 AZD1222 백신의 첫 번째 접종 후 WM, CLL 및 NHL 환자에서 낮은 중화 항체 반응Article Published on 2022-05-012022-09-12 Journal: Clinical and experimental medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age and gender antibodies AZD1222 BNT162b2 booster doses chronic chronic lymphocytic leukemia CLL Control COVID-19 Efficacy first dose Hematological malignancy investigated IQR Macroglobulinemia malignant disease NAb NAb titer NAbs neutralizing antibody Neutralizing antibody response NHL Non-Hodgkin Lymphoma Patient performed response SARS-CoV-2 the median the vaccine treatment initiation vaccination Vaccine Waldenstrom Macroglobulinemia. [DOI] 10.1007/s10238-021-00746-4 PMC 바로가기 [Article Type] Article
Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases면역글로불린 A 혈관염 중증급성호흡기증후군 코로나바이러스 2 백신 접종 후 보고된 사례 검토Article Published on 2022-05-012022-09-12 Journal: The Journal of dermatology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome allergy components coronavirus de novo de novo onset Deterioration Female patients FIVE Hematuria IgA immune immunoglobulin A immunoglobulin A nephropathy immunoglobulin A vasculitis individual individuals involved Patient reported SARS-CoV-2 SARS-CoV-2 vaccination severe acute respiratory syndrome coronavirus 2 vaccination. skin lesion the vaccine vaccination Vasculitis [DOI] 10.1111/1346-8138.16326 PMC 바로가기 [Article Type] Article
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study델타 기간 동안 COVID-19에 대한 mRNA-1273의 내구성: 관찰 코호트 연구의 중간 결과Observational Study Published on 2022-04-282022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adjusted hazard ratios age calculated CIs Cohort conducted COVID-19 COVID-19 hospitalization Cox proportional hazard Cox proportional hazards models death Delta delta variant dose Effectiveness Evidence Follow-up groups hospital individual individuals interim analysis Interim result mRNA mRNA-1273 Observational cohort study outcome prospective cohort study Randomly receiving recipient SARS-COV-2 infection selected Sex the vaccine were used [DOI] 10.1371/journal.pone.0267824 PMC 바로가기 [Article Type] Observational Study
SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infectionSARS-CoV2 야생형 및 돌연변이 특이 체액성 및 T 세포 면역은 자연 감염 후보다 백신 접종 후 우수Article Published on 2022-04-252022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 binding Alpha antibodies antibody Antibody titer Antibody titers B.1.617.2 Blood blood sample Blood samples CD4 CD4+ T cell cytokine production delta variant Finger prick flow cytometric flow cytometric intracellular cytokine staining humoral IFN-γ IL-2 immune response immune responses Immunity Infection intracellular cytokine staining investigated mutant natural infection neutralisation no significant difference overcome pandemic Patient peptide peptides positive RBD RBD binding Receptor binding domain reduced response responses SARS-CoV2 significant difference significantly Specific Spike protein Stimulation strain Strong subject subjects T cell T cell response T cell responses tested the vaccine TNF-α vaccinated individuals vaccination variant variants Virus neutralization was reduced were measured wild type [DOI] 10.1371/journal.pone.0266701 PMC 바로가기 [Article Type] Article
Benefits of integrated screening and vaccination for infection control감염관리를 위한 통합검진 및 예방접종의 장점Article Published on 2022-04-212022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] adverse outcome base Characteristics college Community compartmental model Compliance Coverage COVID-19 infections deaths delta variant develop disease disease spread disease transmission Diseases effective Effectiveness Efficacy Frequency Hospitalization hospitalizations hypothetical infection control Infectious diseases initial Intervention Model parameter predominant reduce Reproduction number reproduction numbers Safe Screening sensitivity analysis the vaccine Transmission vaccination vaccination rate Vaccination strategies Vaccine [DOI] 10.1371/journal.pone.0267388 PMC 바로가기 [Article Type] Article